Chembio Diagnostics, Inc. (CEMI): Price and Financial Metrics


Chembio Diagnostics, Inc. (CEMI): $2.00

0.11 (+5.82%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CEMI POWR Grades


  • Value is the dimension where CEMI ranks best; there it ranks ahead of 69.87% of US stocks.
  • The strongest trend for CEMI is in Momentum, which has been heading down over the past 52 weeks.
  • CEMI's current lowest rank is in the Sentiment metric (where it is better than 2.19% of US stocks).

CEMI Stock Summary

  • CEMI has a market capitalization of $56,785,316 -- more than approximately just 8.71% of US stocks.
  • In terms of volatility of its share price, CEMI is more volatile than 89.65% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CEMI comes in at -68.24% -- higher than that of just 4.26% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Chembio Diagnostics Inc are IBIO, SANW, AVGR, CPSI, and GEOS.
  • Visit CEMI's SEC page to see the company's official filings. To visit the company's web site, go to chembio.com.

CEMI Valuation Summary

  • CEMI's price/earnings ratio is -3; this is 108.22% lower than that of the median Healthcare stock.
  • Over the past 209 months, CEMI's price/sales ratio has gone down 1.3.
  • Over the past 209 months, CEMI's price/earnings ratio has gone up 1.8.

Below are key valuation metrics over time for CEMI.

Stock Date P/S P/B P/E EV/EBIT
CEMI 2021-08-31 2.2 5.2 -3.0 -4.2
CEMI 2021-08-30 2.3 5.3 -3.1 -4.3
CEMI 2021-08-27 2.4 5.7 -3.3 -4.5
CEMI 2021-08-26 2.2 5.1 -2.9 -4.1
CEMI 2021-08-25 2.2 5.1 -3.0 -4.1
CEMI 2021-08-24 2.1 5.0 -2.9 -4.1

CEMI Growth Metrics

  • The 2 year cash and equivalents growth rate now stands at -9.79%.
  • Its 4 year price growth rate is now at 63.99%.
  • Its 4 year revenue growth rate is now at 34.1%.
Over the past 33 months, CEMI's revenue has gone up $4,062,625.

The table below shows CEMI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 37.47188 -28.89083 -27.06958
2021-06-30 35.68591 -27.46491 -26.24253
2021-03-31 34.33497 -20.49654 -25.02194
2020-12-31 32.4702 -18.88724 -25.52133
2020-09-30 29.09398 -16.80419 -22.27106
2020-06-30 28.54244 -9.300075 -20.51526

CEMI's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CEMI has a Quality Grade of F, ranking ahead of 4.04% of graded US stocks.
  • CEMI's asset turnover comes in at 0.59 -- ranking 57th of 682 Pharmaceutical Products stocks.
  • NEOG, CLVS, and ENDP are the stocks whose asset turnover ratios are most correlated with CEMI.

The table below shows CEMI's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.590 0.400 -0.488
2021-03-31 0.508 0.329 -0.488
2020-12-31 0.492 0.265 -0.504
2020-09-30 0.457 0.251 -0.430
2020-06-30 0.472 0.265 -0.404
2020-03-31 0.642 0.334 -0.343

CEMI Price Target

For more insight on analysts targets of CEMI, see our CEMI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.00 Average Broker Recommendation 1.83 (Hold)

CEMI Stock Price Chart Interactive Chart >

Price chart for CEMI

CEMI Price/Volume Stats

Current price $2.00 52-week high $8.75
Prev. close $1.89 52-week low $1.78
Day low $1.92 Volume 2,011,300
Day high $2.07 Avg. volume 5,600,167
50-day MA $2.32 Dividend yield N/A
200-day MA $3.24 Market Cap 60.09M

Chembio Diagnostics, Inc. (CEMI) Company Bio


Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. The company was founded in 1985 and is based in Medford, New York.


CEMI Latest News Stream


Event/Time News Detail
Loading, please wait...

CEMI Latest Social Stream


Loading social stream, please wait...

View Full CEMI Social Stream

Latest CEMI News From Around the Web

Below are the latest news stories about Chembio Diagnostics Inc that investors may wish to consider to help them evaluate CEMI as an investment opportunity.

Chembio Diagnostics rises 8% after-hours after submitting EUA for COVID test

Shares of Chembio Diagnostics (NASDAQ:CEMI) are up 8% in after-hours trading after announcing that it has submitted an Emergency Use Authorization to the FDA for its DPP SARS-CoV-2 Antigen test. The test is designed to provide results in 20 minutes and use a minimally invasive nasal swab. The test was developed with...

Seeking Alpha | November 16, 2021

Chembio Diagnostics Submits EUA Application for New DPP SARS-CoV-2 Antigen Test

HAUPPAUGE, N.Y., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the submission of an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for the new DPP SARS-CoV-2 Antigen test. Previously, Chembio received an award from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human S

Yahoo | November 16, 2021

Chembio Diagnostics Announces Extension of Delivery Schedule for Bio Manguinhos Purchase Order of DPP SARS-COV-2 Antigen Tests

HAUPPAUGE, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (“Chembio”) (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced that the delivery schedule for shipments of DPP SARS-COV-2 Antigen Tests under its July 2021 purchase order from Bio Manguinhos has been extended into March 2021. As the result of a portion of the shipments now being deliverable after year end, Chembio believes it now has the opportunity to fulfill all

Yahoo | November 15, 2021

Dimensional Fund Advisors LP Has $162,000 Stock Holdings in Chembio Diagnostics, Inc. (NASDAQ:CEMI)

Dimensional Fund Advisors LP cut its stake in Chembio Diagnostics, Inc. (NASDAQ:CEMI) by 18.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,662 shares of the companys stock after selling 12,426 shares during the period. Dimensional Fund Advisors LP owned approximately []

Transcript Daily | November 11, 2021

Shareholders in Chembio Diagnostics (NASDAQ:CEMI) are in the red if they invested five years ago

Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...

Yahoo | November 9, 2021

Read More 'CEMI' Stories Here

CEMI Price Returns

1-mo -11.89%
3-mo -28.83%
6-mo -38.27%
1-year -63.10%
3-year -69.42%
5-year -71.43%
YTD -57.89%
2020 4.17%
2019 -19.43%
2018 -30.98%
2017 20.59%
2016 27.58%

Continue Researching CEMI

Want to see what other sources are saying about Chembio Diagnostics Inc's financials and stock price? Try the links below:

Chembio Diagnostics Inc (CEMI) Stock Price | Nasdaq
Chembio Diagnostics Inc (CEMI) Stock Quote, History and News - Yahoo Finance
Chembio Diagnostics Inc (CEMI) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7238 seconds.